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angiographic and procedural variables. Comparison was adjusted on 4 strata of
the propensity score.
Results: Between 2002 and 2008, 223 patients were treated: 114 with BMS
and 110 with DES. Most of the patients with BMS between 2002 and 2004
and later with DES. No significant difference was observed in clinical charac-
teristics between groups: age 70 years, reference diameter 2.40±0.60mm,
lesion length 10±9mm. Two cases of coronary perforation occurred, 7 lesion
failure, and 12 transcient no-reflow. The use of GP2b3a inhibitors was similar
in both groups, but, compared with BMS, patients in the DES group had
longer duration of combination of aspirin and Clopidogrel. At one year, signi-
ficantly lower rates of vessel revascularisation (2% vs 12%, p=0.005), of all
cause mortality (5% vs 14%, p=0.05) and of MACE (10% vs 22%, p=0.02)
were observed in the DES than in the BMS group. Adjustment on the strata of
the propensity score did not change significantly these results (figure).
Conclusions: Despite propensity score adjusted, this comparison has limita-
tions. After rotational atherectomy we observed clear benefit for DES implanta-
tion over BMS on vessel revascularisation, mortality and MACE rates.
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Background: Numerous recent studies showed that about 4 to 30% of patients
treated with conventional doses of clopidogrel do not display adequate antiplatelet
response and then the concept of clopidogrel resistance has arisen. Recently, a
number of observations have indicated that patients with diabetes mellitus (DM)
exhibit persistent platelet activation and low response after antiplatelet therapy.
Objective: The purpose of this study was to establish the prevalence and
the predictive factors of the resistance to clopidogrel in a coronary artery
disease population, using ex vivo measure of platelet aggregation: the cone
and platelet analyzer.
Methods: The population of this prospective study was comprised of 105
patients with acute coronary syndrome. Mean age was 57.8 ± 10.8 years, 81.9
% were males, 36,5% patients had history of hypertension, 54,3% patients were
diabetic. Patients were given a loading dose of 300-600 mg followed by a main-
tenance dose of 75 mg on top of a maintenance dose of aspirin ranging from 125
mg to 250 mg. Platelet aggregation was assessed using the Impact R (Diamed®).
The degree of platelet adherence was evaluated as a percentage of surface cove-
rage (SC). Residual platelet reactivity was defined as a SC ≤ 2.8 %.
Results: The mean surface coverage was of 7.78 + 4.29 %. We found that
17.1 % of our population was clopidogrel resistant. By univariate analysis
female sex and diabetes were associated with an increased incidence of clopi-
dogrel resistance, nevertheless, by multivariate analysis, diabetes was the only
independent predictive factor, (OR=3.5, IC 952[1.1-11.4]; P=0.0039). The pre-
valence of clopidogrel resistance was higher in diabetic patients compared to
non diabetics (24.6% vs 8.3%; p=0.02) respectively. This prevalence was
greater in diabetic patients treated by insulin (30%). Concomitant medication
did not influence the incidence of clopidogrel resistance in particular the use
of Omeprazol and Atorvastatin.
Conclusions: Diabetic patients do not respond well to the available antipla-
telet regimen when compared with similar patients without DM. The clinical
implications of these findings are unknown but are potentially important.
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Background: Gamma’ fibrinogen (γ’Fg) is a Fg isoform that constitutes about
15% of total plasma Fg and contains an additional binding site for factor XIII and
for IIa forming clots that are resistant to fibrinolysis in vitro. Little is known about
γ’Fg in the pathophysiology of Acute Coronary Syndrome (ACS) patients.
Aim: To compare γ’Fg level and the relation with fibrin clot physical pro-
perties in a young post-MI patients matched for age and gender and age with
healthy controls.
Method: γ’Fg was measured in duplicates in 260 young post-MI patients
and n=260 controls. Maximum fibrin elastic modulus (EM in dyne/cm2), a
measure of clot stiffness (G’) and Clot Lysis Time (CLT in sec) a measure of
fibrinolysis rate were measured in all subject.
Results: Patients produced stiffer plasma fibrin with increased EM
(24.4±15.9 vs 13.5±5.9 kdynes/cm2 ; p<0.0001) with reduced fibrinolysis
speed (1038±797 vs 595±416 sec; p<0.0001) in comparison with controls.
γ’Fg concentration was significantly higher in patients compared to control
(Figure 1) (p=0.037). However the ratio of γ’Fg over total Fg concentration
(% of γ’Fg) was similar in both groups (3.7± 2% vs 3.5± 2.7% in controls;
p=0.49). In patients there was a stepwise increase in clot stiffness (EM) with ter-
tile of γ’Fg concentration (T1=13.7±7 T2=19.8±14 T3=23.7±16 in kdynes/cm2)
with a similar effect on hypofibrinolysis (CLT) (T1=675±550 T2=829±680 T3=
940±750) (p<0.0001 for both).
Conclusion: γ’Fg concentration was found to be significantly higher in
young post-MI patients as compared to healthy controls matched for age and
gender and may account for the great differences in fibrin clot physical pro-
perties between patients and controls, an independent correlate of premature
coronary artery disease.
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